Patents by Inventor Mark Connelly

Mark Connelly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10945428
    Abstract: This invention relates to a preservative solution and a method to preserve whole blood for cellular and molecular analysis.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: March 16, 2021
    Assignee: Menarini Silicon Biosystems S.p.A.
    Inventors: Mark Connelly, Chandra Galla Rao, Denis Smirnov
  • Patent number: 10597722
    Abstract: Compositions, systems and methods for the diagnosing the risk of acute myocardial infarction are provided. The methods described herein relate to the use of biomarkers, such as gene expression profiles, and analytical tools for providing information to a health care provider or the patient, that is relevant to the cardiovascular health of the patient.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: March 24, 2020
    Assignees: SCRIPPS HEALTH, ORTHO-CLINICAL DIAGNOSTICS, INC.
    Inventors: Eric J. Topol, Evan Muse, Mark Connelly, Timothy Jatkoe, Haiying Wang
  • Publication number: 20180291456
    Abstract: Compositions, systems and methods for the diagnosing the risk of acute myocardial infarction are provided. The methods described herein relate to the use of biomarkers, such as gene expression profiles, and analytical tools for providing information to a health care provider or the patient, that is relevant to the cardiovascular health of the patient.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 11, 2018
    Inventors: Eric J. TOPOL, Evan MUSE, Mark CONNELLY, Timothy JATKOE, Haiying WANG
  • Patent number: 10041120
    Abstract: Compositions, systems and methods for the diagnosing the risk of acute myocardial infarction are provided. The methods described herein relate to the use of biomarkers, such as gene expression profiles, and analytical tools for providing information to a health care provider or the patient, that is relevant to the cardiovascular health of the patient.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: August 7, 2018
    Assignees: SCRIPPS HEALTH, ORTHO-CLINICAL DIAGNOSTICS, INC.
    Inventors: Eric J. Topol, Evan Muse, Mark Connelly, Timothy Jatkoe, Haiying Wang
  • Publication number: 20180055041
    Abstract: This invention relates to a preservative solution and a method to preserve whole blood for cellular and molecular analysis.
    Type: Application
    Filed: March 3, 2017
    Publication date: March 1, 2018
    Inventors: Mark Connelly, Chandra Galla Rao, Denis Smirnov
  • Publication number: 20150361496
    Abstract: Compositions, systems and methods for the diagnosing the risk of acute myocardial infarction are provided. The methods described herein relate to the use of biomarkers, such as gene expression profiles, and analytical tools for providing information to a health care provider or the patient, that is relevant to the cardiovascular health of the patient.
    Type: Application
    Filed: May 15, 2015
    Publication date: December 17, 2015
    Inventors: Eric J. TOPOL, Evan MUSE, Mark CONNELLY, Timothy JATKOE, Haiying WANG
  • Publication number: 20140295426
    Abstract: A method for diagnosing or differentially diagnosing a cancer characterized by the presence of cancer cells in the pleural fluid of a mammalian subject, the method comprising contacting a sample of pleural fluid of the subject with colloidal magnetic particles coupled to a ligand which binds to a determinant on a cancer cell, but does not bind above a baseline threshold to other cellular and non-cellular components in pleural fluid; subjecting the pleural fluid-magnetic particle mixture to a magnetic field to produce a cell fraction enriched in ligand coupled-magnetic particle-bound cancer cells, if present in the pleural fluid; and analyzing the enriched fraction for the number of cancer cells in the pleural fluid. In certain aspects, this method involves preparing the pleural fluids for the above-noted method steps by, e.g., dilution of unprocessed pleural fluid. In certain aspect, the pleural fluid is subjected to the diagnostic method within 24 hours of withdrawal from the subject.
    Type: Application
    Filed: July 27, 2012
    Publication date: October 2, 2014
    Applicants: VERIDEX LLC, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Steven M. Albelda, Daniel Schwed, Chandra Galla Rao, Mark Connelly, Brad Foulk
  • Publication number: 20130157347
    Abstract: Compositions, systems, and methods comprising circulating endothelial cells (CECs) are provided. The compositions described herein utilize isolated CECs, including compositions in a form that allows analysis of the CECs. The systems described herein utilize isolated CECs and an analytical tool or an output from an analytical tool. The methods described herein are related to the use of isolated CECs and analytical tools for providing information, to a health care provider or the CEC donor, that is relevant to the cardiovascular health of the CEC donor. Thus, the compositions, systems and methods described herein involve both a transformation (e.g., non-isolated CECs to isolated CECs, or isolated CECs to analyzed CECs) and a machine (e.g., isolation tools and analytical tools).
    Type: Application
    Filed: July 6, 2012
    Publication date: June 20, 2013
    Applicants: Veridex, LLC, Scripps Health
    Inventors: Eric Topol, Samir Damani, Mark Connelly, Galla Chandra Rao
  • Publication number: 20070154960
    Abstract: Elevated number of Circulating Endothelial Cells (CEC) have been implicated in disease conditions associated with the formation or destruction of blood vessels such as acute coronary syndrome, thrombocytopenic purpura, sickle cell disease, sepsis, lupus, nephrotic syndromes, rejection of organ transplants, surgical trauma and cancer. This invention provides a method for assessing the levels of CEC which vary between different studies using a sensitive enrichment, imaging, and enumberation analysis. CD146 is one of the most specific endothelium-associated cell-surface antigens which can be used in image cytometry. CEC analysis provides an essential tool in prognostic/diagnostic evaluation in the clinic.
    Type: Application
    Filed: February 2, 2007
    Publication date: July 5, 2007
    Inventors: Mark Connelly, Gerald Doyle, Galla Rao, Leon Terstappen
  • Publication number: 20060263836
    Abstract: A method and composition for the purpose of detecting and measuring analytes, such as antibodies, which are capable of binding with certain binding partners such as antigens. A homogenous assay is performed in the presence of free unbound antibodies. Such a homogeneous assay testing for specific antibodies is herein possible by defining of test subsets of microparticles having specific antigens thereon which are capable of binding with specific target antibodies. The microparticle suspension also includes at least two calibration subsets of microparticles having a binding partner thereon with at least two known levels of concentration which is capable of binding with human antibodies for the purpose of assay calibration. A verification subset of microparticles is included with another binding partner thereon at a known concentration, capable of binding with anti-human antibodies.
    Type: Application
    Filed: February 23, 2006
    Publication date: November 23, 2006
    Inventors: Mark Connelly, Mark Kopnitsky
  • Patent number: D860635
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: September 24, 2019
    Inventor: Mark Connelly
  • Patent number: D906532
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: December 29, 2020
    Inventor: Mark Connelly